These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7688897)

  • 41. Expression of glycodelin in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastases.
    Shabani N; Mylonas I; Kunert-Keil C; Briese V; Janni W; Gerber B; Friese K; Jeschke U
    Anticancer Res; 2005; 25(3A):1761-4. PubMed ID: 16033096
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis.
    Redondo M; García J; Villar E; Rodrigo I; Perea-Milla E; Serrano A; Morell M
    Hum Pathol; 2003 Dec; 34(12):1283-9. PubMed ID: 14691914
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of c-kit in common benign and malignant breast lesions.
    Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
    Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization and distribution in normal and tumoral human tissues of breast cancer-associated antigen defined by monoclonal antibody 7B10.
    Pancino GF; Le Doussal V; Mortada MH; Berthon P; Osinaga E; Calvo F; Roseto A
    Cancer Res; 1989 Dec; 49(24 Pt 1):7078-85. PubMed ID: 2555058
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer.
    Edwards DP; Grzyb KT; Dressler LG; Mansel RE; Zava DT; Sledge GW; McGuire WL
    Cancer Res; 1986 Mar; 46(3):1306-17. PubMed ID: 3510721
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
    Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
    Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fibronectin: a discrimination marker between small invasive carcinomas and benign proliferative lesions of the breast.
    Christensen L
    APMIS; 1990 Jul; 98(7):615-23. PubMed ID: 2397113
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The distribution of carcinoembryonic antigen in breast carcinoma. Diagnostic and prognostic implications.
    Kuhajda FP; Offutt LE; Mendelsohn G
    Cancer; 1983 Oct; 52(7):1257-64. PubMed ID: 6192897
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CDw75 is a significant histopathological marker for gastric carcinoma.
    Shen L; Li HX; Luo HS; Shen ZX; Tan SY; Guo J; Sun J
    World J Gastroenterol; 2004 Jun; 10(11):1682-5. PubMed ID: 15162552
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HLA class II sublocus expression in benign and malignant breast epithelium.
    Zuk JA; Walker RA
    J Pathol; 1988 Aug; 155(4):301-9. PubMed ID: 2459333
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer.
    Berry N; Jones DB; Smallwood J; Taylor I; Kirkham N; Taylor-Papadimitriou J
    Br J Cancer; 1985 Feb; 51(2):179-86. PubMed ID: 2578285
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CEA and NCA in benign and malignant breast tumors.
    Nap M; Keuning H; Burtin P; Oosterhuis JW; Fleuren G
    Am J Clin Pathol; 1984 Nov; 82(5):526-34. PubMed ID: 6388310
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential CD133 expression distinguishes malignant from benign papillary lesions of the breast.
    Lin CH; Liu CH; Wen CH; Ko PL; Chai CY
    Virchows Arch; 2015 Feb; 466(2):177-84. PubMed ID: 25433813
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma.
    Schimmelpenning H; Eriksson ET; Falkmer UG; Azavedo E; Svane G; Auer GU
    Virchows Arch A Pathol Anat Histopathol; 1992; 420(5):433-40. PubMed ID: 1350695
    [TBL] [Abstract][Full Text] [Related]  

  • 55. n-butyrate reduces the expression of beta-galactoside alpha 2,6-sialyltransferase in Hep G2 cells.
    Shah S; Lance P; Smith TJ; Berenson CS; Cohen SA; Horvath PJ; Lau JT; Baumann H
    J Biol Chem; 1992 May; 267(15):10652-8. PubMed ID: 1316908
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunocytochemical reactivity of a mouse monoclonal antibody CDI 315B raised against human breast carcinoma.
    Beketić-Oresković L; Sarcević B; Malenica B; Novak D
    Neoplasma; 1993; 40(2):69-74. PubMed ID: 8394515
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Isoantigens A, B and H in benign and malignant lesions of breast.
    Gupta RK; Schuster R
    Am J Pathol; 1973 Aug; 72(2):253-7. PubMed ID: 4807589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast.
    Viale G; Gambacorta M; Coggi G; Dell'Orto P; Milani M; Doglioni C
    Virchows Arch A Pathol Anat Histopathol; 1991; 418(4):339-48. PubMed ID: 1708927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Carcinoma-associated cytostructural antigenic alterations: detection by lectin binding.
    Howard DR; Ferguson P; Batsakis JG
    Cancer; 1981 Jun; 47(12):2872-7. PubMed ID: 6167345
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The basement membrane component laminin in breast carcinomas and axillary lymph node metastases.
    Nielsen M; Christensen L; Albrechtsen R
    Acta Pathol Microbiol Immunol Scand A; 1983 Jul; 91(4):257-64. PubMed ID: 6306989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.